Celiac Diseases Drugs

Global Celiac Diseases Drugs Market to Reach US$2.6 Billion by 2030

The global market for Celiac Diseases Drugs estimated at US$776.2 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 22.2% over the analysis period 2024-2030. First Line Treatment, one of the segments analyzed in the report, is expected to record a 24.4% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Second-Line Treatment segment is estimated at 17.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.5 Million While China is Forecast to Grow at 30.0% CAGR

The Celiac Diseases Drugs market in the U.S. is estimated at US$211.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$629.0 Million by the year 2030 trailing a CAGR of 30.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 20.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.7% CAGR.

Global Celiac Diseases Drugs Market – Key Trends & Drivers Summarized

Why Is the Celiac Disease Drug Market Experiencing a Surge in Demand?

The global celiac disease drug market is witnessing significant growth, driven by an increasing prevalence of diagnosed cases and a heightened awareness of the disease. Celiac disease, an autoimmune disorder triggered by gluten ingestion, affects approximately 1 in 100 individuals in the United States, with many cases remaining undiagnosed . This underdiagnosis underscores the need for effective treatments beyond the traditional gluten-free diet. The limitations of a strict gluten-free diet, including challenges in adherence and the risk of inadvertent gluten exposure, have propelled the demand for pharmaceutical interventions. Patients are seeking alternative therapies that can mitigate the immune response triggered by gluten, leading to the development of novel drugs targeting various aspects of the disease`s pathophysiology. These include agents that degrade gluten peptides, modulate the immune system, or protect the intestinal lining. The growing pipeline of such drugs indicates a shift towards more comprehensive management strategies for celiac disease.

How Are Technological Advancements Influencing Treatment Options?

Technological innovations in drug development are playing a pivotal role in expanding treatment options for celiac disease. Advancements in biotechnology have facilitated the creation of enzyme therapies designed to break down gluten peptides before they can trigger an immune response. Additionally, research into immunomodulatory treatments aims to induce tolerance to gluten, potentially offering a long-term solution for patients. These cutting-edge therapies are currently undergoing clinical trials, with some showing promising results in reducing intestinal inflammation and improving patient outcomes.

Moreover, the integration of personalized medicine approaches is enabling the development of treatments tailored to individual patient profiles. By analyzing genetic, immunological, and microbiome data, researchers can identify specific targets for intervention, enhancing the efficacy of new therapies. This precision medicine paradigm is expected to revolutionize the management of celiac disease, offering more effective and individualized treatment options.

What Role Do Regulatory and Market Dynamics Play in Shaping the Industry?

Regulatory frameworks and market dynamics are significantly influencing the trajectory of the celiac disease drug market. The designation of orphan drug status for certain celiac disease treatments by regulatory bodies provides incentives such as market exclusivity and tax credits, encouraging pharmaceutical companies to invest in this area. These incentives are crucial in offsetting the high costs associated with drug development and clinical trials.

Market dynamics, including increased funding for research and development, are also contributing to the growth of the industry. Public and private investments are fueling the discovery of novel therapeutic targets and the advancement of clinical trials. Additionally, collaborations between biotech firms and academic institutions are fostering innovation and accelerating the translation of research findings into viable treatments. These factors collectively create a conducive environment for the expansion of the celiac disease drug market.

What Are the Key Drivers Propelling Market Growth?

The growth in the celiac disease drug market is driven by several factors. Foremost is the increasing prevalence of diagnosed celiac disease cases, which heightens the demand for effective treatments. Technological advancements in drug development, particularly in enzyme therapies and immunomodulators, are expanding the therapeutic arsenal available to patients. The limitations of the gluten-free diet, including challenges in adherence and the risk of cross-contamination, underscore the need for pharmaceutical interventions. Regulatory incentives, such as orphan drug designations, are encouraging investment in celiac disease research and development. Furthermore, heightened awareness and advocacy efforts are leading to earlier diagnosis and increased patient engagement, further fueling market expansion. Collectively, these factors are propelling the celiac disease drug market towards sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Celiac Diseases Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy Type (First Line Treatment, Second-Line Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospitals & Specialty Clinics, Specialty Pharmacies, Retail Pharmacies, Online Platforms)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• ActoBio Therapeutics
• Allero Therapeutics B.V.
• Amgen Inc.
• Anokion SA
• BioLineRx Ltd.
• Calypso Biotech
• Dr. Falk Pharma GmbH
• Entero Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd
• Immunic Therapeutics
• ImmusanT Inc.
• Innovate Biopharmaceuticals
• Johnson & Johnson
• Merck & Co., Inc.
• Nemysis Ltd.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zedira GmbH

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.